Biomarin Pharmaceutical (BMRN) Net Income Growth (3y) (2012 - 2026)
Biomarin Pharmaceutical (BMRN) Net Income Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - | 9.16% |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | 79.26% |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 47.10% |
| 10 | Biomarin Pharmaceutical | 11.67 Bn | 9.45 Bn | 571.21 Mn | 27.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.55% |
| Dec 31, 2025 | -471.89% |
| Sep 30, 2025 | -66.57% |
| Jun 30, 2025 | 105.63% |
| Mar 31, 2025 | 15.41% |
| Dec 31, 2024 | 60.80% |
| Sep 30, 2024 | 69.93% |
| Jun 30, 2024 | 102.32% |
| Mar 31, 2024 | 72.18% |
| Dec 31, 2023 | 6.16% |
| Sep 30, 2023 | -62.81% |
| Jun 30, 2023 | 57.68% |
| Mar 31, 2023 | -14.51% |
| Dec 31, 2022 | -26.34% |
| Sep 30, 2022 | -28.48% |
| Jun 30, 2022 | 39.91% |
| Mar 31, 2022 | 60.56% |
| Dec 31, 2021 | -151.26% |
| Sep 30, 2021 | -42.47% |
| Jun 30, 2021 | 40.45% |